TSC-102-A01
Hematologic malignancies
PreclinicalIND Cleared
Key Facts
About TScan Therapeutics
TScan Therapeutics is a fully integrated, clinical-stage biotech focused on unleashing the immune system through TCR-T cell therapies. Founded in 2018, the company's lead program, TSC-101, is in a Phase 1 trial for AML and MDS, and it has a pipeline of candidates for solid tumors and autoimmune disorders. TScan differentiates itself with a proprietary platform for target discovery and is advancing both ex vivo and in vivo engineered T cell approaches.
View full company profileTherapeutic Areas
Other Hematologic malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1905 | Jiangsu Hengrui Medicine | Phase 1 |
| Rituximab biosimilar (IBI301) | Innovent Biologics | Approved |
| Alemtuzumab Biosimilar | CSPC Pharmaceutical Group Limited | Phase 3 |
| Lead CAR-T Program | Arcellx | Phase 1 |
| KT-333 | Kymera Therapeutics | Phase 1 |
| Undisclosed CAR-T programs | Beam Therapeutics | Discovery/Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Oncology Program |
| Cord Blood HSC Unit | Global Cord Blood | Approved/Commercial |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1 |
| CER-T Cell Platform | CERo Therapeutics | Pre-clinical |